Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2020

Open Access 01-12-2020 | Radiotherapy | Review

First statement on preparation for the COVID-19 pandemic in large German Speaking University-based radiation oncology departments

Authors: Stephanie E. Combs, Claus Belka, Maximilian Niyazi, Stefanie Corradini, Steffi Pigorsch, Jan Wilkens, Anca L. Grosu, Matthias Guckenberger, Ute Ganswindt, Denise Bernhardt

Published in: Radiation Oncology | Issue 1/2020

Login to get access

Abstract

The COVID-19 pandemic is challenging modern radiation oncology. At University Hospitals, we have a mandate to offer high-end treatments to all cancer patients. However, in times of crisis we must learn to prioritize resources, especially personnel. Compromising oncological outcome will blur all statistics, therefore all measures must be taken with great caution. Communication with our neighboring countries, within societies and between departments can help meet the challenge. Here, we report on our learning system and preparation measures to effectively tackle the COVID-19 challenge in University-Based Radiation Oncology Departments.
Literature
1.
2.
3.
4.
Rocklov J, Sjodin H, Wilder-Smith A. COVID-19 outbreak on the diamond princess cruise ship: estimating the epidemic potential and effectiveness of public health countermeasures. J Travel Med. 2020.
5.
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020:102433.
6.
Adhikari SP, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1):29.PubMedPubMedCentralCrossRef
7.
Baumann M, et al. Radiation oncology in the era of precision medicine. Nat Rev Cancer. 2016;16(4):234–49.PubMedCrossRef
8.
Filippi AR, Russi E, Magrini SM, Corvò R. Covid-19 outbreak in northern Italy: First Practical Indications for Radiotherapy Departments. Int J Radiat Oncol Biol Phys. 2020.
9.
Budach W, Bolke E, Matuschek C. Hypofractionated Radiotherapy as Adjuvant Treatment in Early Breast Cancer. A Review and Meta-Analysis of Randomized Controlled Trials. Breast Care (Basel). 2015;10(4):240–5.CrossRef
10.
Hocht S, et al. Hypofractionated radiotherapy for localized prostate cancer. Strahlenther Onkol. 2017;193(1):1–12.PubMedCrossRef
11.
Eccles SA, et al. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res. 2013;15(5):R92.PubMedPubMedCentralCrossRef
12.
Douglas S, et al. Prognostic factors for different outcomes in patients with metastatic spinal cord compression from cancer of unknown primary. BMC Cancer. 2012;12:261.PubMedPubMedCentralCrossRef
13.
Douglas S, Schild SE, Rades D. Metastatic spinal cord compression in patients with cancer of unknown primary. Estimating the survival prognosis with a validated score. Strahlenther Onkol. 2012;188(11):1048–51.PubMedCrossRef
14.
15.
Rades D, Abrahm JL. The role of radiotherapy for metastatic epidural spinal cord compression. Nat Rev Clin Oncol. 2010;7(10):590–8.PubMedCrossRef
16.
Rades D, Bajrovic A, Bartscht T. Predictive factors and a survival score for patients irradiated for metastatic spinal cord compression from carcinoma of the salivary glands. Anticancer Res. 2017;37(12):7011–5.PubMed
17.
Rades D, et al. Forecasting survival probabilities after radiotherapy of metastatic epidural spinal cord compression from colorectal Cancer in the elderly. Anticancer Res. 2016;36(4):1829–33.PubMed
18.
Rades D, et al. Dose escalation for metastatic spinal cord compression in patients with relatively radioresistant tumors. Int J Radiat Oncol Biol Phys. 2011;80(5):1492–7.PubMedCrossRef
19.
Combs SE, et al. Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score-report of the radiation oncology group (ROG) of the German Cancer consortium (DKTK). Cancer Med. 2018;7(5):1742–9.PubMedPubMedCentralCrossRef
20.
Niyazi M, et al. Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: a multicenter DKTK/ROG analysis. Radiother Oncol. 2018;127(1):121–7.PubMedCrossRef
21.
Niyazi M, et al. Validation of the prognostic Heidelberg re-irradiation score in an independent mono-institutional patient cohort. Radiat Oncol. 2014;9:128.PubMedPubMedCentralCrossRef
22.
Kessel KA, Combs SE. Digital biomarkers: importance of patient stratification for re-irradiation of glioma patients - review of latest developments regarding scoring assessment. Phys Med. 2019;67:20–6.PubMedCrossRef
23.
Kessel KA, et al. Modification and optimization of an established prognostic score after re-irradiation of recurrent glioma. PLoS One. 2017;12(7):e0180457.PubMedPubMedCentralCrossRef
24.
Kessel KA, et al. Validation of an established prognostic score after re-irradiation of recurrent glioma. Acta Oncol. 2017;56(3):422–6.PubMedCrossRef
25.
Rades D, et al. Prognostic factors predicting functional outcomes, recurrence-free survival, and overall survival after radiotherapy for metastatic spinal cord compression in breast cancer patients. Int J Radiat Oncol Biol Phys. 2006;64(1):182–8.PubMedCrossRef
26.
27.
28.
Li R, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). In: Science; 2020.
29.
Nacoti, M.C. A; Giupponi A; Brambillasca P; Lussana F; Pisano M; Goisis, G; Bonacina, D; Fazzi, F; Naspro, R; Longhi, L; Cereda, M; Montaguti, C, At the Epicenter of the Covid-19 Pandemic and Humanitarian Crises in Italy: Changing Perspectives on Preparation and Mitigation. N Engl J Med Catalyst, 2020. in press.
30.
The First Affiliated Hospital, Z.U.S.o.M. Handbook of COVID-290 Prevention and Treatment. 2020.
31.
Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020.
32.
33.
Perry JR, Laperriere N, Mason WP. Radiation plus Temozolomide in patients with Glioblastoma. N Engl J Med. 2017;376(22):2197.PubMedCrossRef
34.
Roa W, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22(9):1583–8.PubMedCrossRef
35.
Malmstrom A, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916–26.PubMedCrossRef
36.
Stupp R, et al. Maintenance therapy with tumor-treating fields plus Temozolomide vs Temozolomide alone for Glioblastoma: a randomized clinical trial. JAMA. 2015;314(23):2535–43.PubMedCrossRef
37.
Kocher M, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29(2):134–41.PubMedCrossRef
38.
Yamamoto M, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;15(4):387–95.CrossRefPubMed
39.
Brown PD, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316(4):401–9.PubMedPubMedCentralCrossRef
40.
Mahajan A, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-Centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1040–8.PubMedPubMedCentralCrossRef
41.
Sahgal A, et al. Stereotactic radiosurgery alone for multiple brain metastases? A review of clinical and technical issues. Neuro-Oncology. 2017;19(suppl_2):ii2–ii15.PubMedPubMedCentralCrossRef
42.
Borgelt B, et al. Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys. 1981;7(12):1633–8.PubMedCrossRef
43.
Mulvenna P, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet. 2016;388(10055):2004–14.PubMedPubMedCentralCrossRef
44.
Alfredo C, et al. Normofractionated stereotactic radiotherapy versus CyberKnife-based hypofractionation in skull base meningioma: a German and Italian pooled cohort analysis. Radiat Oncol. 2019;14(1):201.PubMedPubMedCentralCrossRef
45.
Goldbrunner R, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016;17(9):e383–91.PubMedCrossRef
46.
Rogers L, et al. Intermediate-risk meningioma: initial outcomes from NRG oncology RTOG 0539. J Neurosurg. 2018;129(1):35–47.PubMedCrossRef
47.
Nilsson C, Valachis A. The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: a meta-analysis of observational studies. Radiother Oncol. 2015;114(1):50–5.PubMedCrossRef
48.
Haviland JS, et al. The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086–94.PubMedCrossRef
49.
Brunt AM, et al. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-forward trial. Radiother Oncol. 2016;120(1):114–8.PubMedPubMedCentralCrossRef
50.
group, F.T, et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). Radiother Oncol. 2011;100(1):93–100.CrossRef
51.
Wang SL, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2019;20(3):352–60.PubMedCrossRef
52.
Correa C, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol. 2017;7(2):73–9.PubMedCrossRef
53.
Livi L, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer. 2015;51(4):451–63.PubMedCrossRef
54.
Vaidya JS, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014;383(9917):603–13.PubMedCrossRef
55.
Veronesi U, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013;14(13):1269–77.PubMedCrossRef
56.
Videtic GM, et al. Long-term follow-up on NRG oncology RTOG 0915 (NCCTG N0927): a randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung Cancer. Int J Radiat Oncol Biol Phys. 2019;103(5):1077–84.PubMedCrossRef
57.
Guckenberger M, et al. Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol. 2013;8(8):1050–8.PubMedCrossRef
58.
Sculier JP, et al. A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer. Ann Oncol. 2008;19(10):1691–7.PubMedCrossRef
59.
Murray N, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada clinical trials group. J Clin Oncol. 1993;11(2):336–44.PubMedCrossRef
60.
Hamdy FC, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate Cancer. N Engl J Med. 2016;375(15):1415–24.PubMedCrossRef
61.
Zapatero A, et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(3):320–7.PubMedCrossRef
62.
Bolla M, et al. Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate Cancer: results of EORTC trial 22991. J Clin Oncol. 2016;34(15):1748–56.PubMedCrossRef
63.
Dearnaley D, Hall E. Prostate cancer and hypofractionation: reflections on recent randomised phase III clinical trial results. Transl Androl Urol. 2017;6(1):134–6.PubMedPubMedCentralCrossRef
64.
Dearnaley D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047–60.PubMedPubMedCentralCrossRef
65.
Widmark A, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394(10196):385–95.PubMedCrossRef
66.
Pommier P, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study. Int J Radiat Oncol Biol Phys. 2016;96(4):759–69.PubMedCrossRef
67.
Pommier P, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol. 2007;25(34):5366–73.PubMedCrossRef
68.
Supiot S, et al. Hypofractionated radiotherapy in prostate cancer. Cancer Radiother. 2013;17(5–6):349–54.PubMedCrossRef
69.
Chow E, et al. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol. 2007;25(11):1423–36.PubMedCrossRef
70.
Spanos W Jr, et al. Phase II study of multiple daily fractionations in the palliation of advanced pelvic malignancies: preliminary report of RTOG 8502. Int J Radiat Oncol Biol Phys. 1989;17(3):659–61.PubMedCrossRef
71.
Sapienza LG, et al. Short-course palliative radiation therapy leads to excellent bleeding control: a single Centre retrospective study. Clin Transl Radiat Oncol. 2019;14:40–6.PubMedCrossRef
72.
Otake S, Goto T. Stereotactic Radiotherapy for Oligometastasis. Cancers (Basel). 2019;11(2).
73.
Yom SS, Harari PM. When disaster strikes: mitigating the adverse impact on head and neck Cancer patients. Int J Radiat Oncol Biol Phys. 2018;100(4):838–40.PubMedCrossRef
74.
Sandler HM. Role of overall treatment time in the Management of Prostate Cancer Patients: how to manage unscheduled treatment interruptions. Int J Radiat Oncol Biol Phys. 2018;100(4):841–2.PubMedCrossRef
75.
Roach MC, Robinson CG, Bradley JD. Natural disasters and the importance of minimizing subsequent radiation therapy interruptions for locally advanced lung Cancer. Int J Radiat Oncol Biol Phys. 2018;100(4):836–7.PubMedCrossRef
76.
Gay HA, et al. Lessons learned from hurricane Maria in Puerto Rico: practical measures to mitigate the impact of a catastrophic natural disaster on radiation oncology patients. Pract Radiat Oncol. 2019;9(5):305–21.PubMedCrossRef
77.
Achard V, et al. Twice- vs. thrice-weekly moderate hypofractionated radiotherapy for prostate cancer: does overall treatment time matter? J Cancer Res Clin Oncol. 2019;145(6):1581–8.PubMedCrossRef
Metadata
Title
First statement on preparation for the COVID-19 pandemic in large German Speaking University-based radiation oncology departments
Authors
Stephanie E. Combs
Claus Belka
Maximilian Niyazi
Stefanie Corradini
Steffi Pigorsch
Jan Wilkens
Anca L. Grosu
Matthias Guckenberger
Ute Ganswindt
Denise Bernhardt
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2020
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-020-01527-1

Other articles of this Issue 1/2020

Radiation Oncology 1/2020 Go to the issue

Research

Is local radiotherapy a viable option for patients with an opening of the ventricles during surgical resection of brain metastases?

Research

Treatment planning comparison of volumetric modulated arc therapy employing a dual-layer stacked multi-leaf collimator and helical tomotherapy for cervix uteri

Research

The dosimetric impact of replacing the TG-43 algorithm by model based dose calculation for liver brachytherapy

Review

Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy

Research

CPAP (Continuous Positive Airway Pressure) is an effective and stable solution for heart sparing radiotherapy of left sided breast cancer

Research

A nomogram based on pretreatment CT radiomics features for predicting complete response to chemoradiotherapy in patients with esophageal squamous cell cancer